Piramal Pharma Limited has informed the Exchange regarding Change in Director(s) of the company.

Piramal Pharma's board approved FY26 audited financial results (standalone and consolidated) with an unmodified auditor opinion from Suresh Surana & Associates LLP. Four directors were re-appointed: Chairperson Nandini Piramal and CEO Peter DeYoung as Executive Directors for 3 more years, and Independent Directors Sridhar Gorthi and Peter Stevenson for a second 5-year term. Mr. Maneesh Sharma was appointed as the new Company Secretary and Compliance Officer from April 29, 2026, replacing interim CS Ms. Pratibha Mishra. The registered office address is being updated effective April 30, 2026. On a standalone basis, FY26 revenue fell about 9.5% to Rs 4,782 crore while net profit edged up to Rs 700 crore (EPS Rs 5.28). On a consolidated basis, the company swung to a net loss of Rs 326 crore versus a Rs 91 crore profit last year, mainly due to Rs 196 crore of exceptional items including a Rs 65.57 crore impairment charge and Rs 26.94 crore impact from new Labour Codes.